Bioequivalence Study of Two Fixed Dose Combination Tablet Formulations of Lopinavir and Ritonavir in Healthy Volunteers
Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam | PLOS ONE
![Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings | Thorax Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings | Thorax](https://thorax.bmj.com/content/thoraxjnl/59/3/252/F1.large.jpg)
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings | Thorax
![Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective | Psychiatrist.com Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective | Psychiatrist.com](https://www.psychiatrist.com/PublishingImages/20com02677T1.gif)
Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective | Psychiatrist.com
![Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial - The Lancet HIV Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial - The Lancet HIV](https://www.thelancet.com/cms/attachment/9e2160f1-f0ab-460d-b6f2-54ba0a214318/gr1.gif)
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial - The Lancet HIV
LOPINAVIR/RITONAVIR MYLAN 1. Product Name 2. Qualitative and Quantitative Composition 3. Pharmaceutical Form 4. Clinical Particu
![Reduced dose darunavir/ritonavir effective and safe for people switching while virally suppressed | aidsmap Reduced dose darunavir/ritonavir effective and safe for people switching while virally suppressed | aidsmap](https://www.aidsmap.com/sites/default/files/styles/aidsmap_social_default/public/2018-07/reduced-dose-darunavir-ritonavir-effective-and-safe-for-people-switching-while-virally-suppressed.jpg?itok=ZWEWUWgd)
Reduced dose darunavir/ritonavir effective and safe for people switching while virally suppressed | aidsmap
![Re: Acknowledgement of human bioequivalency of matrix's lopinavir–ritonavir formulation to Kaletra®, comment to article on bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al. - Re: Acknowledgement of human bioequivalency of matrix's lopinavir–ritonavir formulation to Kaletra®, comment to article on bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al. -](https://jpharmsci.org/cms/attachment/2046476358/2057584760/gr1.jpg)